Compare Avantis US Small Cap Value ETF (AVUV) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis US Small Cap Value ETF vs Novartis AG — how do they compare? Avantis US Small Cap Value ETF trades at $124.88, while Novartis AG trades at $149.88 (market cap $288.65B). The key difference: Novartis AG pays a 3.15% dividend while Avantis US Small Cap Value ETF pays none, and Avantis US Small Cap Value ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| AVUV | NVS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $124.94 | $168.62 |
52-Week Low | $90.37 | $113.50 |
Market Cap | — | $288.65B |
Enterprise Value | — | $328.67B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVUV trades at $123.97, up 0.02% on the day, with a bullish technical outlook supported by moving averages. The ETF focuses on U.S. small-cap value stocks, which have outperformed growth peers in 2026, driven by shifting rate expectations. Recent news highlights its role in diversifying tech-heavy portfolios and capturing the small-cap value premium.
Outlook remains positive as small-cap value gains favor amid economic shifts, though risks include higher volatility and sensitivity to interest rates. The fund offers growth potential but requires tolerance for the inherent risks of smaller companies.
Novartis (NVS) trades at $153.37, down 0.44% today, with a bullish technical signal from moving averages. The company reported $56.67B revenue in 2025 with strong profitability margins (net income margin 23.92%) and recently expanded its oncology pipeline through acquisitions like Myricx Bio. Earnings have been mixed, with a miss in Q1 2026 but a beat in Q4 2025.
Outlook remains stable with revenue projections near $56.6B for 2026, though debt-to-asset ratio has risen to 30.26%. Risks include pipeline execution and competitive pressures. Analysts show cautious optimism with 68% hold ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
